Abstract
Introduction and Objectives Vitamin D (VD) is involved in immunity and inflammation through mechanisms such as renin inhibition and inflammatory cytokine reduction. There is already evidence to suggest that VDD may increase COVID-19 infection susceptibility, however research assessing the impact of VDD on COVID-19 symptom duration is limited. The aim of this research was to determine whether VDD is a significant independent risk factor for extended durations of COVID-19 symptoms.
Methods The study included 392 healthcare workers who isolated due to COVID-19 symptoms during the first wave of the pandemic (12th to 22nd May 2020) as part of the convalescent immunity (COCO) study. Data on 8 symptom types and duration of symptoms were collected, including patients’ demographics and co-morbidities. Anti-SARS-Cov-2 antibodies were measured using a combined IgG, IgA and IgM ELISA (The Binding Site). Vitamin D status was determined by measurement of serum 25(OH)D3 using the AB SCIEX Triple Quad 4500 mass spectrometry system. VDD was defined as serum 25(OH)D3 lt;30 nmol/L.
Results Through univariate analysis of VDD and non-VDD staff, we initially showed VDD to be significantly associated with longer durations of body aches (median 7 days, IQR 5textendash14 vs. median 5 days, IQR 3textendash7.5; p=0.0075) and fatigue (median 12 days, IQR 7textendash14 vs. median 7 days, IQR 4textendash14; p=0.0127). VDD did not influence the duration of the other 6 symptoms analysed, such as cough and fever. Using binary logistic regression models, we confirm that VDD is a significant independent risk factor for extended durations of fatigue (OR 2.089, 95.087textendash4.011; p=0.027) and body aches (OR 3.069, 95.538textendash6.124; p=0.001). Additionally, VDD staff experienced a significantly greater quantity of symptoms compared to non-VDD staff (median 5, IQR 4textendash7 versus median 4, IQR 3textendash6; p=0.0030).
Conclusions This is one of the first studies to investigate the influence of VDD on COVID-19 symptom duration. Our results indicate that VDD is a significant independent risk factor for a longer duration of body aches and fatigue. Larger studies are required to confirm these results and determine if VD supplementation could shorten symptoms.
Methods The study included 392 healthcare workers who isolated due to COVID-19 symptoms during the first wave of the pandemic (12th to 22nd May 2020) as part of the convalescent immunity (COCO) study. Data on 8 symptom types and duration of symptoms were collected, including patients’ demographics and co-morbidities. Anti-SARS-Cov-2 antibodies were measured using a combined IgG, IgA and IgM ELISA (The Binding Site). Vitamin D status was determined by measurement of serum 25(OH)D3 using the AB SCIEX Triple Quad 4500 mass spectrometry system. VDD was defined as serum 25(OH)D3 lt;30 nmol/L.
Results Through univariate analysis of VDD and non-VDD staff, we initially showed VDD to be significantly associated with longer durations of body aches (median 7 days, IQR 5textendash14 vs. median 5 days, IQR 3textendash7.5; p=0.0075) and fatigue (median 12 days, IQR 7textendash14 vs. median 7 days, IQR 4textendash14; p=0.0127). VDD did not influence the duration of the other 6 symptoms analysed, such as cough and fever. Using binary logistic regression models, we confirm that VDD is a significant independent risk factor for extended durations of fatigue (OR 2.089, 95.087textendash4.011; p=0.027) and body aches (OR 3.069, 95.538textendash6.124; p=0.001). Additionally, VDD staff experienced a significantly greater quantity of symptoms compared to non-VDD staff (median 5, IQR 4textendash7 versus median 4, IQR 3textendash6; p=0.0030).
Conclusions This is one of the first studies to investigate the influence of VDD on COVID-19 symptom duration. Our results indicate that VDD is a significant independent risk factor for a longer duration of body aches and fatigue. Larger studies are required to confirm these results and determine if VD supplementation could shorten symptoms.
Original language | English |
---|---|
Pages (from-to) | A170-A171 |
Journal | Thorax |
Volume | 77 |
Issue number | Suppl 1 |
Early online date | 11 Nov 2022 |
DOIs | |
Publication status | Published - 7 Jul 2023 |
Event | British Thoracic Society Winter Meeting 2022 - QEII Centre, London , United Kingdom Duration: 23 Nov 2022 → 25 Nov 2022 |